The Future of Heart Valve Treatment: Proven Therapies and Patient Impact
-
21m 25s
-
15m 51s
This webinar, part of the Beyond the Heartbeat series, explored the latest advancements in mitral and tricuspid regurgitation treatment. An expert panel shared details related to groundbreaking clinical trial data and practical insights to enhance professional practice.
The session addressed several key learning objectives: recent clinical data from the CLASP IID™ and TRISCEND II™ trials, showcasing the benefits of minimally invasive therapies; the significance of under-referral of mitral/tricuspid regurgitation patients, and their impact on patient outcomes and quality of life; and effective strategies for patient identification and referral to ensure timely and appropriate treatment.
The webinar provided an opportunity to stay at the forefront of heart valve treatment and improve patient outcomes.
Learning Objectives
- Explore Proven Therapies: Discover recent clinical data from the CLASP IIDTM and TRISCEND IITM trials, showcasing the benefits of minimally invasive therapies.
- Address Critical Gaps: Recognize the significance of under-referral of mitral/tricuspid regurgitation patients, and their impact on patient outcomes and quality of life.
- Implement Best Practices: Learn effective strategies for patient identification and referral to ensure timely and appropriate treatment.
Target Audience
- Referring Cardiologists
More from this programme
Part 1
Introduction
In this opening session of The Future of Heart Valve Treatment: Proven Therapies and Patient Impact, Dr Brian O'Neill, initially introduces the session and all faculty, as well as covering key disclosures.
| 1 session | |
| Introduction | Watch now |
Part 2
CLASP IID™ and TRISCEND II™ Data Presentation
In the second part of this video series, Dr Brian O'Neil explores recent clinical data from the CLASP IID™ and TRISCEND II™ trials, highlighting benefits of minimally invasive therapies.
Part 3
Roundtable: Challenges in Management and Referral of MR/TR Patients
The roundtable addressed critical gaps in the management of mitral and tricuspid regurgitation, focusing on underdiagnosis, under referral, and undertreatment. Dr Bryan Zweig, Dr Ryan Gandi, and Dr Brian O’Neil discussed how these issues previously affected patient outcomes and quality of life.
Part 4
Roundtable: Practical Solutions to Implement Today
The roundtable explored practical strategies for improving patient identification and referral to support timely, effective treatment. Dr Bryan Zweig, Dr Ryan Gandi, and Dr Brian O’Neil shared best practices used in clinical settings.
Faculty Biographies
Brian O’Neill
Brian O’Neill, MD is an Associate Professor of Medicine at Wayne State University School of Medicine. Brian O’Neill, MD is a Structural heart interventionist at Henry Ford Hospital and is the Director of Structural Heart Research which was recently recognized at the TCT 2024 conference as the number one structural heart research program in the country. He has a particular interest in mitral and tricuspid heart disease and has authored numerous abstracts and manuscripts. Brian O’Neill, MD currently serves as a co-PI on multiple different trials for novel devices in mitral and tricuspid disease. He enjoys traveling and skiing in his free time and is the proud father of four young children.
Comments